The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Could Vitamin D Be the Missing Ingredient in HCV Therapy?

Back to News Homepage

Next

Hep C Discrimination in the Workplace

Encouraging Start for New HCV Treatment Concept

December 11, 2009

Print this page

By thinking outside the box, the Denmark-based company Santaris Pharma A/S has developed a drug targeting a specific molecule necessary for Hepatitis C replication. Although a very small trial, SPC3649 demonstrates a significant Hepatitis C viral load decline in primates.

New Hepatitis C Treatment Shows Promise

Drug prevented virus from replicating in the livers of primates

By Jennifer Thomas
HealthDay Reporter

THURSDAY, Dec. 3 (HealthDay News) — A new drug to treat hepatitis C has shown promise in a primate study.

The drug, called SPC3649, uses a new strategy to prevent the hepatitis C virus from replicating. Unlike other antivirals that target the virus itself, the new DNA-based drug targets a small RNA molecule in the liver that hepatitis C needs to replicate, the researchers explained.

By inhibiting the molecule, SPC3649 reduced hepatitis C virus levels in the liver and in the bloodstream in chimpanzees that received the highest dose by 350-fold.

Continue reading the entire article:
http://health.usnews.com/articles/health/healthday/2009/12/03/new-hepatitis-c-treatment-shows-promise.html

No Comments - be the first!
Share
Share

Previous

Could Vitamin D Be the Missing Ingredient in HCV Therapy?

Back to News Homepage

Next

Hep C Discrimination in the Workplace

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.